Codiak BioSciences, Inc. (CDAK) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Codiak BioSciences, Inc. (CDAK) Healthcare & Pipeline Overview

Codiak BioSciences, Inc. pioneers exosome-based therapeutics, targeting oncology and neurological diseases. With a focus on novel drug delivery, Codiak leverages its proprietary platform to develop treatments for solid tumors and other challenging conditions, positioning itself in the competitive biotechnology landscape alongside established pharmaceutical companies.

What Is the Investment Thesis for CDAK?

Codiak BioSciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's proprietary exosome platform offers a novel approach to drug delivery, potentially addressing limitations of traditional methods. Key value drivers include the clinical progress of exoSTING and exoIL-12 in oncology, with upcoming data readouts expected in 2027. Successful clinical trials and subsequent regulatory approvals could significantly increase the company's valuation. However, the company's negative profit margin of -181.5% underscores the financial risks associated with early-stage biotechnology companies. Investor sentiment and market conditions will also play a crucial role in Codiak's stock performance.

Based on FMP financials and quantitative analysis

CDAK Key Highlights

Codiak BioSciences is a clinical-stage biopharmaceutical company focused on exosome-based therapeutics.

• Lead product candidates, exoSTING and exoIL-12, target various solid tumors.
• The company has a gross margin of 100.0%, indicating efficient production processes.
• Codiak has collaboration agreements with Jazz Pharmaceuticals, Sarepta Therapeutics, and other institutions.
• The company's beta of 3.93 suggests high volatility compared to the market.

Who Are CDAK's Competitors?

CDAK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDAK's Key Strengths?

Proprietary exosome technology platform.

• Strong scientific expertise.
• Strategic collaborations.
• Potential for targeted drug delivery.

What Are CDAK's Weaknesses?

Clinical-stage company with no approved products.

• High cash burn rate.
• Dependence on partnerships for funding.
• High beta indicates significant volatility.

What Could Drive CDAK Stock Higher?

Clinical data readouts for exoSTING in solid tumors expected in 2027.

• Initiation of clinical trials for neuro-oncology programs within the next 3-4 years.
• Advancement of the exoVACC platform for precision vaccines.
• Continued strategic partnerships and collaborations.

What Are the Key Risks for CDAK?

Financial-distress signal — its Altman Z-Score of -4.37 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for lead product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies.
• High cash burn rate and dependence on external funding.
• Patent challenges or infringement.

What Are the Growth Opportunities for CDAK?

• Expansion of Oncology Pipeline: Codiak has the opportunity to expand its oncology pipeline beyond exoSTING and exoIL-12. The global oncology market is projected to reach $400 billion by 2030, providing a substantial market opportunity for novel cancer therapies. By developing additional exosome-based therapeutics targeting different cancer types and mechanisms, Codiak can diversify its product portfolio and increase its revenue potential. This expansion requires further investment in research and development, as well as strategic collaborations with academic institutions and other biotechnology companies. Timeline: Ongoing, with new clinical programs expected to enter development in the next 2-3 years.
• Advancement of Neuro-Oncology Programs: Codiak can capitalize on the unmet need for effective treatments for neuro-oncological diseases. The market for neuro-oncology therapeutics is estimated at $5 billion, with significant growth potential due to the increasing incidence of brain tumors and the limited efficacy of existing therapies. By advancing its exosome-based therapies for neuro-oncology, Codiak can address a critical medical need and capture a share of this growing market. This requires demonstrating the ability of its exosome platform to effectively deliver therapeutic payloads across the blood-brain barrier. Timeline: Clinical trials for neuro-oncology programs are expected to commence within the next 3-4 years.
• Development of Precision Vaccines: Codiak's exoVACC platform offers a modular approach to constructing precision vaccines, enabling the development of targeted immunotherapies for infectious diseases and cancer. The global vaccine market is projected to reach $100 billion by 2028, driven by the ongoing COVID-19 pandemic and the increasing demand for preventative healthcare. By leveraging its exosome platform to develop novel vaccines, Codiak can address unmet needs in infectious disease prevention and cancer immunotherapy. This requires demonstrating the safety and efficacy of its exoVACC platform in preclinical and clinical studies. Timeline: Preclinical development is ongoing, with clinical trials expected to begin in the next 2-3 years.
• Strategic Partnerships and Collaborations: Codiak can accelerate the development and commercialization of its exosome-based therapies through strategic partnerships and collaborations with pharmaceutical companies and academic institutions. These partnerships can provide access to additional funding, expertise, and resources, enabling Codiak to expand its pipeline and reach a wider patient population. By forging strategic alliances, Codiak can leverage the strengths of its partners to overcome challenges in drug development and commercialization. Ongoing: Codiak continues to actively seek and cultivate strategic partnerships to advance its programs.
• Expansion into New Therapeutic Areas: Codiak has the potential to expand its exosome platform into new therapeutic areas beyond oncology and neuro-oncology, such as neurology, neuromuscular diseases, and infectious diseases. These areas represent significant unmet medical needs and market opportunities. By leveraging its expertise in exosome engineering and targeted drug delivery, Codiak can develop novel therapies for a wide range of diseases. This requires further investment in research and development, as well as the establishment of new collaborations with experts in these therapeutic areas. Timeline: Exploration of new therapeutic areas is ongoing, with potential for new programs to enter development in the next 3-5 years.

What Are CDAK's Competitive Advantages?

• Proprietary exosome engineering platform.
• Strong intellectual property portfolio.
• Strategic collaborations with leading institutions.
• First-mover advantage in exosome-based therapeutics.

What Does CDAK Do?

Codiak BioSciences, Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of various diseases through exosome-based therapeutics. Exosomes, naturally occurring vesicles secreted by cells, are harnessed by Codiak to deliver therapeutic payloads directly to target cells. This innovative approach aims to overcome the limitations of traditional drug delivery methods, enhancing efficacy and reducing off-target effects. The company's lead product candidates, exoSTING and exoIL-12, are designed to treat a range of solid tumors by stimulating the immune system within the tumor microenvironment. Beyond oncology, Codiak is developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor, and exoVACC, a modular platform for constructing precision vaccines. These programs reflect Codiak's commitment to expanding the therapeutic applications of its exosome platform. The company has established collaborations with leading institutions and pharmaceutical companies, including Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard, to accelerate the development and commercialization of its exosome-based therapies. Codiak's focus on exosome engineering and targeted drug delivery positions it at the forefront of a new era in biopharmaceutical innovation.

What Products and Services Does CDAK Offer?

• Develop exosome-based therapeutics for various diseases.
• Target oncology with lead product candidates exoSTING and exoIL-12.
• Develop exoASO-STAT6 for targeting the STAT6 transcription factor.
• Create exoVACC, a modular platform for precision vaccines.
• Collaborate with pharmaceutical companies and research institutions.
• Focus on targeted drug delivery using exosomes.

How Does CDAK Make Money?

• Develop and commercialize exosome-based therapeutics.
• Generate revenue through partnerships and collaborations.
• Out-license technology to other companies.
• Potentially generate revenue through direct sales of approved therapies in the future.

What Industry Does CDAK Operate In?

Codiak BioSciences operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for targeted drug delivery systems is expanding, driven by the need for more effective and less toxic therapies. Codiak's exosome-based platform positions it within this growing market segment. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel drug delivery technologies. Success in this industry requires strong scientific expertise, strategic partnerships, and the ability to navigate the complex regulatory landscape.

Who Are CDAK's Key Customers?

• Patients with solid tumors.
• Patients with neuro-oncological diseases.
• Pharmaceutical companies through collaborations.
• Research institutions through partnerships.

Codiak BioSciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.37 places it in the distress zone, a signal of elevated financial risk.

CDAK Valuation & Market Position

Relative to its peer group, CDAK's quantitative score of 46/100 is below the peer average of 90/100.

Key Financial Metrics

Return on assets is -24.3%, showing how much profit it generates from its asset base. A current ratio of 3.32 indicates the company holds enough short-term assets to cover its near-term obligations.

Company Profile

Codiak BioSciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Douglas Edward Williams. CDAK has traded publicly since 2020.

CDAK Financials

CDAK Latest News

No recent news available for CDAK.

CDAK Analyst Consensus

CDAK MoonshotScore

What Investors Ask About Codiak BioSciences, Inc. (CDAK) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources